

Special Issue

Pharmacotherapy in the Era of Pandemics: Latest Advances and Prospects

Message from the Guest Editors

Medications should not be considered as static elements or isolated from the physiological phenomena of the human body or their interaction with other medications. They are dynamic tools, with effects that can be modified by multiple factors and whose use must be balanced to optimize the therapeutic objectives sought and to avoid unwanted effects. Additionally, their use should also be supervised by specialists. These are difficult times, times in which the emergence of pathogens potentially capable of spreading to produce pandemics makes the sound of war drums, in which medicines are invaluable. In essence, drugs can act both at the level of prevention and treatment. The sudden emergence of unknown pathogens capable of producing diseases that we are not capable of curing or even alleviating at the time we detect them undoubtedly forces us to investigate to promote the development of these types of drugs. In this Special Issue, all papers will present research on drugs used in emerging infectious or non-infectious diseases, their mechanisms of action, interaction with other drugs or repositioning of drugs not used for their intended use in these diseases.

Guest Editors

Dr. Antonio Gutiérrez-Pizarraya
Dr. Dorota Kopciuch
Dr. Anna Paczkowska

Deadline for manuscript submissions

closed (31 December 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/129599

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).